To view this video content in its entirety, click on the "Access Content" button and login to your account.

If you do not have an account, register for free.

Please note that the account you create here is different than your Keystone Symposia account at www.keystonesymposia.org used to register for our multi-day conferences and is uniquely for viewing our virtual content.


  1      0

On Demand


Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs


Jan 5, 2021 12:00am ‐ Jan 5, 2021 12:00am

Free

Description

Despite having received FDA approval for treatment of Covid-19, antiviral remdesivir is only moderately efficacious against SARS-CoV-2 in the clinic, and improved treatment strategies are urgently needed. To accomplish this goal, we devised a strategy to identify compounds that act synergistically with remdesivir in preventing SARS-CoV-2 replication. We conducted combinatorial high-throughput screening in the presence of submaximal remdesivir concentrations, using a human lung epithelial cell line infected with a clinical isolate of SARS-CoV-2. We identified 20 approved drugs that act synergistically with remdesivir, many with favorable pharmacokinetic and safety profiles. Strongest effects were observed with established antivirals, Hepatitis C virus nonstructural protein 5 A (HCV NS5A) inhibitors velpatasvir and elbasvir. Combination with their partner drugs sofosbuvir and grazoprevir further increased efficacy, increasing remdesivir’s apparent potency 25-fold. We therefore suggest that the FDA-approved Hepatitis C therapeutics Epclusa (velpatasvir/sofosbuvir) and Zepatier (elbasvir/grazoprevir) should be fast-tracked for clinical evaluation in combination with remdesivir to improve treatment of acute SARS-CoV-2 infections.

Speaker(s):

You must be logged in and own this session in order to post comments.

Leo OzurumbaDwight
1/8/21 3:15 pm

Interesting madam. Since increased efficacy of remdesivir’s was observed to potency level 25-fold when Hepatitis C therapeutics Epclusa (velpatasvir/sofosbuvir) and Zepatier (elbasvir/grazoprevir) are synergistically used with Remdesvir, it means we have added options to clinical tools to treat and manage cases of Covid-19. The US FDA will normally want to exhaust their tests to ensure its efficacy is real and it's safety levels good enough. Then, we will be talking of support frrom antivirals in therapeutics against Covid-19. Interesting one. Kudos to Dr Julia and her team for this impactful effort... Leo Nnamdi Ozurumba-Dwight. (Participant in Keystone eSymposia: Drugs and Vaccines for Covid-19) Interesting madam. Since increased efficacy of remdesivir’s was observed to a potency level that was 25-fold when Hepatitis C therapeutics Epclusa (velpatasvir/sofosbuvir) and Zepatier (elbasvir/grazoprevir) are synergistically used with Remdesvir, it means we have added options to clinical tools available to treat and manage cases of Covid-19. US FDA will normally want to exhaust their tests to ensure its efficacy is real and it's safety levels good enough. Then, we will be talking of support frrom new antivirals in therapeutics against Covid-19.. Kudos to Dr Julia and her UCB team. Leo Nnamdi Ozurumba-Dwight. (Participant in Interesting madam. Since increased efficacy of remdesivir’s was observed to a potency level that was 25-fold when Hepatitis C therapeutics Epclusa (velpatasvir/sofosbuvir) and Zepatier (elbasvir/grazoprevir) are synergistically used with Remdesvir, it means we have added options to the clinical tools available to treat and manage mild and severe cases of Covid-19. The US FDA will normally want to exhaust their tests to ensure its efficacy is real and it's safety levels good enough. Then, we will be talking of support frrom antivirals in therapeutics against Covid-19. Interesting one. Kudos to Dr Julia and her team for this impactful effort.. Leo Nnamdi Ozurumba-Dwight , of Walden University College of Health Sc, resident in Nigeria presently. (Participant in Keystone eSymposia with theme:. Antibodies and Vaccines as Drugs for COVID-19, January 2021).

Leo OzurumbaDwight
1/8/21 3:16 pm

Interesting madam. Since increased efficacy of remdesivir’s was observed to potency level 25-fold when Hepatitis C therapeutics Epclusa (velpatasvir/sofosbuvir) and Zepatier (elbasvir/grazoprevir) are synergistically used with Remdesvir, it means we have added options to clinical tools to treat and manage cases of Covid-19. The US FDA will normally want to exhaust their tests to ensure its efficacy is real and it's safety levels good enough. Then, we will be talking of support frrom antivirals in therapeutics against Covid-19. Interesting one. Kudos to Dr Julia and her team for this impactful effort... Leo Nnamdi Ozurumba-Dwight. (Participant in Keystone eSymposia: Drugs and Vaccines for Covid-19) Interesting madam. Since increased efficacy of remdesivir’s was observed to a potency level that was 25-fold when Hepatitis C therapeutics Epclusa (velpatasvir/sofosbuvir) and Zepatier (elbasvir/grazoprevir) are synergistically used with Remdesvir, it means we have added options to clinical tools available to treat and manage cases of Covid-19. US FDA will normally want to exhaust their tests to ensure its efficacy is real and it's safety levels good enough. Then, we will be talking of support frrom new antivirals in therapeutics against Covid-19.. Kudos to Dr Julia and her UCB team. Leo Nnamdi Ozurumba-Dwight. (Participant in Interesting madam. Since increased efficacy of remdesivir’s was observed to a potency level that was 25-fold when Hepatitis C therapeutics Epclusa (velpatasvir/sofosbuvir) and Zepatier (elbasvir/grazoprevir) are synergistically used with Remdesvir, it means we have added options to the clinical tools available to treat and manage mild and severe cases of Covid-19. The US FDA will normally want to exhaust their tests to ensure its efficacy is real and it's safety levels good enough. Then, we will be talking of support frrom antivirals in therapeutics against Covid-19. Interesting one. Kudos to Dr Julia and her team for this impactful effort.. Leo N. Ozurumba-Dwight , of Walden University College of Health Sc, resident in Nigeria presently. (Participant in Keystone eSymposia with theme:. Antibodies and Vaccines as Drugs for COVID-19, January 2021).

Leo OzurumbaDwight
1/8/21 3:20 pm

Interesting madam. Since increased efficacy of remdesivir’s was observed to potency level 25-fold when Hepatitis C therapeutics Epclusa (velpatasvir/sofosbuvir) and Zepatier (elbasvir/grazoprevir) are synergistically used with Remdesvir, it means we have added options to clinical tools to treat and manage cases of Covid-19. The US FDA will normally want to exhaust their tests to ensure its efficacy is real and it's safety levels good enough. Then, we will be talking of support frrom antivirals in therapeutics against Covid-19. Interesting one. Kudos to Dr Julia and her team for this impactful effort... Leo Nnamdi Ozurumba-Dwight. (Participant in Keystone eSymposia: Drugs and Vaccines for Covid-19) Interesting madam. Since increased efficacy of remdesivir’s was observed to a potency level that was 25-fold when Hepatitis C therapeutics Epclusa (velpatasvir/sofosbuvir) and Zepatier (elbasvir/grazoprevir) are synergistically used with Remdesvir, it means we have added options to clinical tools available to treat and manage cases of Covid-19. US FDA will normally want to exhaust their tests to ensure its efficacy is real and it's safety levels good enough. Then, we will be talking of support frrom new antivirals in therapeutics against Covid-19.. Kudos to Dr Julia and her UCB team. Leo Nnamdi Ozurumba-Dwight. (Participant in Interesting madam. Since increased efficacy of remdesivir’s was observed to a potency level that was 25-fold when Hepatitis C therapeutics Epclusa (velpatasvir/sofosbuvir) and Zepatier (elbasvir/grazoprevir) are synergistically used with Remdesvir, it means we have added options to the clinical tools available to treat and manage mild and severe cases of Covid-19. The US FDA will normally want to exhaust their tests to ensure its efficacy is real and it's safety levels good enough. Then, we will be talking of support frrom antivirals in therapeutics against Covid-19. Interesting one. Kudos to Dr Julia and her team for this impactful effort.. Leo Nnamdi Ozurumba-Dwight , of Walden University College of Health Sc, resident in Nigeria presently. (Participant in Keystone eSymposia with theme:. Antibodies and Vaccines as Drugs for COVID-19, January 2021).

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
Number of hours attended:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content